Synopsis The efficacy trials of a tetravalent dengue vaccine (CYD-TDV) has shown excess hospitalizations for dengue among children 2 to 5 years of age (vaccine recipients). The present study aims to evaluate the effect of dengue serostatus on dengue vaccine efficacy and safety . This week’s “MED FACT” discusses a clinical trial from The New England Journal Of Medicine, “Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy”. Authors: S. Sridhar et.
al. Key Takeaways: Tetravalent dengue vaccine (CYD-TDV), protect against severe Virologically Confirmed Dengue (VCD) and hospitalization for VCD in seropositive patients. Objective: To evaluate the effect of dengue serostatus on dengue vaccine efficacy and safety. Study Type: Case-cohort study Participants: 3578 What was the need for this study? In previous efficacy trials of a tetravalent dengue vaccine (CYD-TDV), excess…
